This week, JanssenResearch & Development joins the European Federation of Crohn’s and Ulcerative Colitis Association (EFCCA) and International Foundation for Autoimmune Arthritis (IFAA) to observe World IBD Day and World Autoimmune Arthritis Day (WAAD).
Inflammatory bowel disease (IBD) and autoimmune arthritis represent significant public health issues, with five million people worldwide affected by ulcerative colitis and Crohn’s disease and as many as 120 million individuals affected by rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis worldwide. Such statistics are a staggering reminder of how important it is that we all work together to address inflammatory diseases like these and improve the quality of life for so many people who are managing sever cramps, vomiting and diarrhea caused by IBD; or swollen, painful joints from a form of autoimmune arthritis.
Janssen is focused on exploring new areas of science and establishing unique collaborations, utilizing novel approaches to deliver transformational medicines. We also support ongoing research in the community, serving as the sole industry sponsor for an IFAA patient study aimed at identifying early symptoms of autoimmune arthritis that may inform earlier detection, referrals, diagnosis and treatment.
Tackling complex disorders like these is, and always will be, our number one priority at Janssen as we strive to discover new solutions for patients around the globe.